Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.
Proposed cuts to the Hospital Preparedness Program may limit hospitals’ capacity to manage pandemics, natural disasters, and mass-casualty events affecting U.S. health systems.
Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.